10 assets in Cytomegalovirus Infection

Therapeutic assets addressing Cytomegalovirus Infection, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Foscarnet Cytomegalovirus Infection	City of Hope Medical Center	P4	BB (69)
Valganciclovir Cytomegalovirus Infection	The Methodist Hospital Research Institute	P3	BB (68)
Ganciclovir Cytomegalovirus Infection	City of Hope Medical Center	P3	BB (67)
Letermovir Cytomegalovirus Infection	Fernanda P Silveira, MD, MS	P2	B (57)
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes Cytomegalovirus Infection	M.D. Anderson Cancer Center	P2	CCC (53)
Maribavir Cytomegalovirus Infection	Seoul National University Hospital	P2	CCC (53)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Cytomegalovirus Infection	City of Hope Medical Center	P2	CCC (53)
Adenovirus Specific T- Lymphocytes Cytomegalovirus Infection	Jessie L. Alexander	P1/2	CCC (48)
Epstein-Barr Virus Specific T-Lymphocytes Cytomegalovirus Infection	Jessie L. Alexander	P1/2	CCC (48)
Cytomegalovirus -Specific Cytotoxic T Cells Cytomegalovirus Infection	Jessie L. Alexander	P1/2	CC (47)